EAN 2022 | Updates on inflammatory demyelinating diseases

Hans Lassmann, MD, Medical University of Vienna, Vienna, Austria, discusses past and upcoming developments in the field of inflammatory demyelinating diseases addressed at the European Academy of Neurology (EAN) Annual Congress. The distinction between multiple sclerosis (MS) and other inflammatory autoimmune or demyelinating diseases, such as neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), has been paramount. Although those diseases have shared similarities with MS, they are fundamentally different diseases and require different treatment strategies. The development of novel therapies is essential, as well as identifying which treatment works best for each disease. This interview took place at the 2022 Congress of the EAN in Vienna, Austria.